|
|
Volumn 34, Issue 5, 2002, Pages 1909-1910
|
|
Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneus pancreas-kidney transplantation: Analysis of early outcome
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
STEROID;
TACROLIMUS;
THYMOCYTE ANTIBODY;
CORTICOSTEROID;
DACLIZUMAB;
DRUG DERIVATIVE;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
LYMPHOCYTE ANTIBODY;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID;
CELL PROLIFERATION;
CELL REGENERATION;
CLINICAL ARTICLE;
CONFERENCE PAPER;
CONTROLLED STUDY;
FEMALE;
HUMAN;
KIDNEY TRANSPLANTATION;
MALE;
PANCREAS TRANSPLANTATION;
PRIORITY JOURNAL;
REDUCTION;
RISK FACTOR;
T LYMPHOCYTE;
ADULT;
ARTICLE;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DIABETIC NEPHROPATHY;
DRUG ADMINISTRATION;
DRUG COMBINATION;
IMMUNOLOGY;
INSULIN DEPENDENT DIABETES MELLITUS;
TIME;
TREATMENT OUTCOME;
ADRENAL CORTEX HORMONES;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTILYMPHOCYTE SERUM;
COMPARATIVE STUDY;
DIABETES MELLITUS, INSULIN-DEPENDENT;
DIABETIC NEPHROPATHIES;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMAN;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
MALE;
MYCOPHENOLIC ACID;
PANCREAS TRANSPLANTATION;
TACROLIMUS;
TIME FACTORS;
TREATMENT OUTCOME;
DIABETES MELLITUS, TYPE 1;
HUMANS;
|
|
EID: 0036049560
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(02)03119-6 Document Type: Conference Paper |
|
Times cited : (4)
|
|
References (5)
|
